Meningococcal Vaccines Market

Global Meningococcal Vaccines Market:

The global meningococcal vaccines market size reached US$ 3.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 7.2 Billion by 2032, exhibiting a growth rate (CAGR) of 7.7% during 2024-2032. The increasing burden of meningococcal disease, government immunization programs, ongoing technological advancements, and global health security concerns are driving the primarily driving the market growth.

Meningococcal Vaccines Market Analysis:

• Major Market Drivers: The increasing prevalence of meningococcal disease among young children and adolescents across the globe represents one of the key factors driving the growth of the market. Furthermore, the rising health consciousness among the masses and the adoption of routine immunization are providing a thrust to market growth.
• Key Market Trends: Various product innovations, such as the development of ready-to-use liquid formulations that do not require reconstitution, are also contributing to the market growth. Moreover, extensive research and development (R&D) activities, along with improvements in the healthcare infrastructure, are anticipated to drive the market further.
• Competitive Landscape: Some of the prominent meningococcal vaccine market companies include GlaxoSmithKline Plc, Hualan Biological Engineering Inc., Incepta Pharmaceuticals Limited, Novartis AG, Pfizer Inc., Sanofi S.A., Serum Institute of India Ltd., and Walvax Biotechnology Co. Ltd., among many others.
• Geographical Trends: According to the meningococcal vaccine market dynamics, North America has well-established public health programs and high awareness of meningococcal disease, driving vaccination rates. Moreover, rapid economic growth in Asia Pacific countries drives demand for meningococcal vaccines.
• Challenges and Opportunities: High costs associated with the development of meningococcal vaccines and regulatory hurdles in the approvals of new vaccines are hampering the market's growth. However, continued research and innovation in vaccine development, including novel antigen targets and adjuvants, present opportunities for improving vaccine efficacy and expanding coverage.

Meningococcal Vaccines Market Trends:

Rising Prevalence of Meningococcal Disease

The rising prevalence of meningococcal disease is a significant factor driving the demand for meningococcal vaccines. For instance, according to the World Health Organization (WHO), from November 2022 to January 2023, around 559 cases of meningitis, including 18 deaths, were recorded from Zinder Region, southeast of Niger, compared to 231 cases reported from November 2021 to January 2022. Meningococcal disease, caused by Neisseria meningitidis bacteria, remains a significant global health concern due to its potential for rapid onset, severity, and outbreaks. The high disease burden drives the demand for effective vaccines. These factors are expected to propel the meningococcal vaccines market in the coming years.

Increasing Awareness Programs

Public health campaigns, healthcare provider education, and community outreach efforts have increased awareness about meningococcal disease and the importance of vaccination. For instance, in August 2021, GSK introduced "Ask2BSure," a public health campaign to encourage parents to check with their child's doctor to see if they have meningitis B immunization. Meningococcal disease, often known as meningitis, is a rare but potentially fatal condition. Enhanced understanding promotes vaccine acceptance and uptake. These factors further positively influence the meningococcal vaccines market forecast.

Government Immunization Programs

Many countries have established routine immunization schedules that include meningococcal vaccines, targeting infants, adolescents, and high-risk groups. For example, according to a November 2022 update from the Government of Western Australia Department of Health, the School-Based Immunization Program (SBIP) would provide Diphtheria-tetanus-pertussis (dTpa), HPV (human papillomavirus), and Meningococcal ACWY vaccines to students beginning 2023. Similarly, in August 2023, the Queensland Government planned to invest US$ 90 million over the next three years to offer free meningococcal B vaccine vaccinations for young children and adults, thereby boosting the meningococcal vaccine systems market revenue.

Global Meningococcal Vaccines Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global meningococcal vaccines market report, along with forecasts at the global, regional, and country levels from 2024-2032. Our report has categorized the market based on vaccine type, composition, vaccine serotype, distribution channel, and end user.

Breakup by Vaccine Type:

• Conjugate
• Polysaccharide
• Subcapsular
   

The report has provided a detailed breakup and analysis of the meningococcal vaccines market based on the vaccine type. This includes conjugate, polysaccharide, and subcapsular.

According to the meningococcal vaccines market outlook, conjugate vaccines are composed of polysaccharide antigens from the bacterial capsule of Neisseria meningitidis, chemically linked (conjugated) to a carrier protein. While polysaccharide vaccines contain purified polysaccharide antigens derived from the bacterial capsule of Neisseria meningitidis. Moreover, subcapsular vaccines target specific surface proteins or antigens located within the bacterial capsule or outer membrane of Neisseria meningitidis.

Breakup by Composition:

• Mono Vaccines
• Combination Vaccines
   

The report has provided a detailed breakup and analysis of the meningococcal vaccines market based on the composition. This includes mono vaccines and combination vaccines.

According to the meningococcal vaccines market overview, monovalent vaccines are often in demand during outbreaks or localized epidemics caused by specific meningococcal serogroup. Public health authorities may deploy monovalent vaccines to quickly contain outbreaks and prevent further spread of the disease. While combination vaccines that protect against multiple meningococcal serogroups (e.g., MenACWY) are favored for routine immunization schedules. They streamline vaccination programs by reducing the number of injections and clinic visits required to achieve comprehensive protection.

Breakup by Vaccine Serotype:

• MenACWY
• MenB & Manic
• MenC
• MenA
• MenAC
• Others
   

A detailed breakup and analysis of the meningococcal vaccines market based on the vaccine serotype has also been provided in the report. This includes MenACWY, MenB & Manic, MenC, MenA, MenAC, and others.

MenACWY vaccines protect against meningococcal serogroups A, C, W, and Y. While MenB vaccines target meningococcal serogroup B. MenB vaccines are typically recombinant protein-based or outer membrane vesicle (OMV) vaccines. They contain antigens specific to serogroup B, which are distinct in structure from serogroups A, C, W, and Y. Moreover, MenAC vaccines target meningococcal serogroups A and C. Apart from this, MenA vaccines specifically target meningococcal serogroup A. These are typically monovalent vaccines containing polysaccharide antigens from serogroup A Neisseria meningitidis. Furthermore, MenACWY-DT vaccines combine antigens from meningococcal serogroups A, C, W, and Y.

Breakup by Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Institutional Sales
• Others
   

A detailed breakup and analysis of the meningococcal vaccines market based on the distribution channel has also been provided in the report. This includes hospital pharmacies, retail pharmacies, institutional sales, and others.

Hospitals often administer meningococcal vaccines to patients admitted for various reasons, including those at higher risk of contracting meningococcal disease due to immunocompromised status or underlying conditions. Hospital pharmacies may provide vaccinations to individuals requiring preventive care or as part of travel medicine services. While retail pharmacies cater to the general public, offering convenient access to meningococcal vaccines for individuals seeking preventive healthcare. Apart from this, institutional sales involve large-scale procurement of meningococcal vaccines for public health programs, such as national immunization schedules targeting specific age groups or high-risk populations.

Breakup by End User:

• Pediatric
• Adult
   

A detailed breakup and analysis of the meningococcal vaccines market based on the end user has also been provided in the report. This pediatric and adult.

Meningococcal vaccines, such as MenACWY, are included in routine childhood immunization schedules in many countries. Vaccination typically begins in infancy and continues through childhood, with doses administered according to national guidelines. While young adults who missed meningococcal vaccination during adolescence may receive catch-up doses, especially before entering college or university. College and university dormitories often require proof of meningococcal vaccination, boosting demand among this age group.

Breakup by Region:

• North America
  • United States
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa
   

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa.

According to the meningococcal vaccines market statistics, the rising prevalence of meningococcal disease in North America is a primary driver. Meningococcal infections can lead to severe outcomes, including meningitis and sepsis, which have spurred vaccination efforts. While stringent healthcare policies and regulations in Europe support the adoption and inclusion of meningococcal vaccines in national immunization schedules. This regulatory environment provides stability and encourages vaccine development and distribution. Apart from this, the Asia Pacific region has seen an increase in the incidence of meningococcal disease, prompting higher demand for vaccines.

Competitive Landscape:

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major market companies have also been provided. Some of the key players in the market include: 

• GlaxoSmithKline Plc
• Hualan Biological Engineering Inc.
• Incepta Pharmaceuticals Limited
• Novartis AG
• Pfizer Inc.
• Sanofi S.A.
• Serum Institute of India Ltd.
• Walvax Biotechnology Co. Ltd.
   

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

Meningococcal Vaccines Market Recent Developments:

• April 2024: The FDA started an assessment of GSK's five-in-one meningococcal vaccine. The new vaccine, which combines GSK's previously authorized vaccines Bexsero and Menveo, is intended to protect against meningitis and blood poisoning caused by the bacteria Neisseria meningitidis serogroups A, B, C, W, and Y (MenABCWY).
• April 2024: Nigeria launched a new vaccine named Men5CV recommended by the World Health Organization (WHO) that protects against five strains of meningococcus bacteria.
• October 2023: The US Food and Drug Administration approved Penbraya, meningococcal vaccine made by Pfizer, which protects against the five most frequent serogroups that cause disease in children and young adults.

Meningococcal Vaccines Market Report Scope:

Key Questions Answered in This Report

• How has the global meningococcal vaccines market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the global meningococcal vaccines market?
• What are the key regional markets?
• What is the breakup of the market based on the vaccine type?
• What is the breakup of the market based on the composition?
• What is the breakup of the market based on the vaccine serotype?
• What is the breakup of the market based on the distribution channel?
• What is the breakup of the market based on the end user?
• What are the various stages in the value chain of the industry?
• What are the key driving factors and challenges in the industry?
• What is the structure of the global meningococcal vaccines market and who are the key players?
• What is the degree of competition in the industry?

Key Benefits for Stakeholders:

• IMARC's report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the meningococcal vaccines market from 2018-2032.
• The research study provides the latest information on the market drivers, challenges, and opportunities in the global meningococcal vaccines market.
• The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
• Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the meningococcal vaccines industry and its attractiveness.
• The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.